- Home
- NMCO vs RLAY Comparison
NMCO vs RLAY Comparison
Compare NMCO & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- RLAY
- Stock Information
- Founded
- NMCO 2019
- RLAY 2015
- Country
- NMCO United States
- RLAY United States
- Employees
- NMCO N/A
- RLAY N/A
- Industry
- NMCO Finance/Investors Services
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMCO Finance
- RLAY Health Care
- Exchange
- NMCO Nasdaq
- RLAY Nasdaq
- Market Cap
- NMCO 577.1M
- RLAY 576.1M
- IPO Year
- NMCO N/A
- RLAY 2020
- Fundamental
- Price
- NMCO $10.83
- RLAY $3.51
- Analyst Decision
- NMCO
- RLAY Strong Buy
- Analyst Count
- NMCO 0
- RLAY 11
- Target Price
- NMCO N/A
- RLAY $18.40
- AVG Volume (30 Days)
- NMCO 207.6K
- RLAY 1.6M
- Earning Date
- NMCO 01-01-0001
- RLAY 08-05-2025
- Dividend Yield
- NMCO 5.43%
- RLAY N/A
- EPS Growth
- NMCO N/A
- RLAY N/A
- EPS
- NMCO N/A
- RLAY N/A
- Revenue
- NMCO N/A
- RLAY $7,679,000.00
- Revenue This Year
- NMCO N/A
- RLAY $14.31
- Revenue Next Year
- NMCO N/A
- RLAY N/A
- P/E Ratio
- NMCO N/A
- RLAY N/A
- Revenue Growth
- NMCO N/A
- RLAY N/A
- 52 Week Low
- NMCO $8.52
- RLAY $1.78
- 52 Week High
- NMCO $11.64
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- NMCO 71.10
- RLAY 56.86
- Support Level
- NMCO $10.46
- RLAY $3.10
- Resistance Level
- NMCO $10.58
- RLAY $3.53
- Average True Range (ATR)
- NMCO 0.13
- RLAY 0.23
- MACD
- NMCO 0.03
- RLAY 0.00
- Stochastic Oscillator
- NMCO 87.50
- RLAY 75.21
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).